Daily Market Recap
optionsXpress background Login Market Recap Briefing.com In Play Late day global & sector ETF movers… Nat Gas strongest play & Ag/Chem weakest space The Actively Traded Leading Global & Sector ETF Plays:
nat gas- UNG +3.50%, iShares REITS & real estate- ICF +2.75%, IYR +2.50%, copper- JJC +1.25%, semis- IGW +1.0%, XSD +1.0%, SMH +0.75%, homebuilders & home construction- ITB +1.0%, XHB +0.50%, base metals- DBB +1.0%, solar power- TAN +0.75%, livestock commods- COW +0.75%, SPDRS cons disct- XLY +0.75% The Actively Traded Lagging Global & Sector ETF Plays:
ag/chem- MOO -1.25%, commercial banks- KBE -1.0%, regional banks- KRE -1.0%, oil HLDRS- OIH -1.0%, iShares Malaysia- EWM -1.0%, gold miners- GDX -0.75%, iShares Taiwan – 0.75%, iShares Chile- ECH -0.50%, global shippers- SEA -0.50%, iShares healthcare providers- IHF -0.50% Earnings Calendar Today after the close look for the following companies to report: ADTN, CSX, HCSG, INTC, and LLTC. Tomorrow before the open look for the following companies to report: IGTE, JPM, MTOX, PGR, and GWW.
Sun Life: S&P lowers ratings on most Sun Life companies by one notch Standard & Poor`s Ratings Services said that it lowered its long-term counterparty credit and financial strength ratings on Sun Life Financial Inc.`s (SLF) core insurance subsidiaries–Sun Life Assurance Co. of Canada (SLA), Sun Life Assurance Co. of Canada (U.S.) (SLUS), and Sun Life Insurance & Annuity Co. of New York–to `AA-` from `AA`. Standard & Poor`s also said that it lowered its financial strength ratings on Independence Life & Annuity Co., which benefits from an explicit claims guarantee for policyholder obligations provided by SLUS–to `AA-` from `AA`. The outlook on these companies is stable. In addition, Standard & Poor`s lowered its long-term counterparty credit rating on SLF to `A` from `A+`. The outlook on SLF in negative. The ratings and outlook on SLF`s Hong Kong subsidiary, Sun Life Hong Kong Ltd. (A+/Stable/—), remain unchanged Great Minds Trade AlikeSM New Trading PatternsSM .
(PATENT PENDING) Look into the collective conscious of our traders and find potential trading opportunities. Only at optionsXpress. Baxter and New York-Presbyterian/Weill Cornell announce 18-month data from phase II study of GAMMAGARD in patients with Alzheimer`s disease Co announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D for mild-to-moderate Alzheimer`s disease. After 18 months, patients who received GAMMAGARD continuously averaged approximately 1.36 points higher than patient who initially received placebo on the ADCS-CGIC. Patients who received GAMMAGARD continuously declined by approximately 9.15 fewer ADAS-Cog points than patients who initially received placebo. Being presented for the first time, MRI analyses showed that patients who received GAMMAGARD continuously for 18 months experienced decreased mean annual ventricular enlargement rates in their brains, compared to control patients who initially received placebo. The decreased rates of ventricular enlargement correlated with clinical outcomes in patients who received continuous GAMMAGARD for 18 months, as measured using the ADCS-CGIC and the ADAS-Cog. In addition, patients who received GAMMAGARD continuously for 18 months experienced lower mean annual whole brain atrophy rates, compared to control patients who initially received placebo. The decreased rates of whole brain atrophy correlated with clinical outcomes in patients who received continuous GAMMAGARD for 18 months, as measured using the ADCS-CGIC and the ADAS-Cog.
Stock indices break above narrow afternoon range highs with Dow +26 joining Nasdaq Comp +8.9 at fresh 52-wk highs S&P +1.7 still hovering slightly under yesterday`s yearly high at 1199.20 (session high 1198.31). Sector relative strength on the latest push has been led by Energy OIH / XLE, Commodity, Retail XRT, Finance XLF, REITS IYR, Ag/Chem MOO.
Kimball Int`l announced that its Indiana production facility has met all the necessary requirements for AS9100 registration ConocoPhillips confirms E-GasTM Technology selected for POSCO gasification project Co confirms the completion of an agreement with POSCO (PKX) to use ConocoPhillips` E-Gas Technology in POSCO`s Gwangyang coal-to-substitute natural gas project. The project will allow POSCO to produce 500,000 metric tons of pipeline quality SNG annually from the gasification of ~1.8 million tons of coal. Preliminary design work began in 2008 and site preparation is now underway.
Avanir Pharmaceuticals presents Zenvia long-term efficacy data Co announced long-term efficacy data from the 12-week double-blind phase and the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating Zenvia in the treatment of pseudobulbar affect (PBA) in patients with underlying multiple sclerosis or amyotrophic lateral sclerosis. Poster highlights include: POSTER HIGHLIGHTS — Zenvia 30/10 mg demonstrated persistent long-term efficacy and tolerability as a therapy for PBA with 92.9% of patients completing the 12-week treatment period of the open-label extension study — Patients who continued on Zenvia 30/10 mg or titrated up from Zenvia 20/10 mg to Zenvia 30/10 mg demonstrated statistically significant incremental improvement in their CNS-LS scores at end of study compared to open-label baseline (p<0.0001 for both groups) — Patients originally on placebo in the double-blind phase who initiated Zenvia 30/10 mg in the open-label phase demonstrated statistically significant improvement in their CNS-LS scores at end of study compared to open-label baseline — At the last study visit (Day 84) of the open-label extension, the mean CNS-LS score was below the cut-off value indicative of clinical PBA.
CONCLUSIONS: In the open-label phase, Zenvia 30/10 mg continued to improve CNS-LS scores over the additional 12-week treatment period demonstrating that the new low-dose formulation provides long-term efficacy as a treatment for reducing the frequency and severity of PBA. More In Play…
Indexes & Quotes DJIA 11,019.42 13.45 S&P 500 1,197.30 0.82 QQQQ 49.32 0.25 NASDAQ 2,465.99 8.12 CBOE VIX 16.20 0.62 More market data…
OX Put/Call Ratios Long Short 0.41 0.73 View more…
optionsXpress Most Actives Option Change RUT 1.97 SPX 0.82 INTC 0.23 AAPL 0.14 QQQQ 0.25 FAZ -0.04 CLF -0.51 GLD -0.32 SPY 0.09 GOOG 14.04 View more…
DTI Optionetics Schaeffer`s Research Power Options You are currently subscribed to optionsXpress Market Recap email as “” .
Related posts: